189 related articles for article (PubMed ID: 30356163)
1. Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.
Danylesko I; Bukauskas A; Paulson M; Peceliunas V; Gedde-Dahl D Y T; Shimoni A; Shouval R; Griskevicius L; Floisand Y; Nagler A
Bone Marrow Transplant; 2019 Jul; 54(7):987-993. PubMed ID: 30356163
[TBL] [Abstract][Full Text] [Related]
2. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review.
Fløisand Y; Lazarevic VL; Maertens J; Mattsson J; Shah NN; Zachée P; Taylor A; Akbari M; Quadri S; Parfionovas A; Chen YB
Biol Blood Marrow Transplant; 2019 Apr; 25(4):720-727. PubMed ID: 30468919
[TBL] [Abstract][Full Text] [Related]
3. Vedolizumab in highly resistant acute gastrointestinal graft-versus-host disease after allogeneic stem cell transplantation: A single-center pediatric series.
Rosa M; Jarmoliński T; Miśkiewicz-Migoń I; Liszka K; Miśkiewicz-Bujna J; Panasiuk A; Frączkiewicz J; Ussowicz M
Adv Clin Exp Med; 2022 Mar; 31(3):345-350. PubMed ID: 35212198
[TBL] [Abstract][Full Text] [Related]
4. Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease.
Fløisand Y; Lundin KEA; Lazarevic V; Kristiansen JD; Osnes LTN; Tjønnfjord GE; Reims HM; Gedde-Dahl T
Biol Blood Marrow Transplant; 2017 Jan; 23(1):172-175. PubMed ID: 27777142
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab for pediatric patients with gastrointestinal acute graft-versus-host-disease.
Aldouby Bier G; Zaidman I; Dinur Schejter Y; NaserEddin A; Stepensky P; Even-Or E
Pediatr Blood Cancer; 2023 Jan; 70(1):e30061. PubMed ID: 36326084
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab for children with intestinal graft-versus-host disease: a case report and literature review.
Fukuta T; Muramatsu H; Yamashita D; Sajiki D; Maemura R; Tsumura Y; Yamamori A; Imaya M; Wakamatsu M; Nishikawa E; Narita K; Kataoka S; Taniguchi R; Narita A; Nishio N; Takahashi Y
Int J Hematol; 2023 Sep; 118(3):411-417. PubMed ID: 37074509
[TBL] [Abstract][Full Text] [Related]
9. α4β7 Integrin expression and blockade in pediatric and young adult gastrointestinal graft-versus-host disease.
Ibrahimova A; Davies SM; Lane A; Jordan MB; Lake K; Litts B; Chaturvedi V; Owsley E; Myers KC; Nelson AS; Mehta PA; Marsh RA; Khandelwal P
Pediatr Blood Cancer; 2021 Aug; 68(8):e28968. PubMed ID: 33861521
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
12. Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases.
Ungar B; Kopylov U; Yavzori M; Fudim E; Picard O; Lahat A; Coscas D; Waterman M; Haj-Natour O; Orbach-Zingboim N; Mao R; Chen M; Chowers Y; Eliakim R; Ben-Horin S
Clin Gastroenterol Hepatol; 2018 May; 16(5):697-705.e7. PubMed ID: 29223444
[TBL] [Abstract][Full Text] [Related]
13. Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease.
Isshiki K; Kamiya T; Endo A; Okamoto K; Osumi T; Kawai T; Arai K; Tomizawa D; Ohtsuka K; Nagahori M; Imai K; Kato M; Kanegane H
Int J Hematol; 2022 Apr; 115(4):590-594. PubMed ID: 34724153
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab for acute gastrointestinal graft-versus-host disease: A systematic review and meta-analysis.
Li AC; Dong C; Tay ST; Ananthakrishnan A; Ma KS
Front Immunol; 2022; 13():1025350. PubMed ID: 36439135
[TBL] [Abstract][Full Text] [Related]
15. A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease.
Fløisand Y; Schroeder MA; Chevallier P; Selleslag D; Devine S; Renteria AS; Mohty M; Yakoub-Agha I; Chen C; Parfionovas A; Quadri S; Jansson J; Akbari M; Chen YB
Bone Marrow Transplant; 2021 Oct; 56(10):2477-2488. PubMed ID: 34108672
[TBL] [Abstract][Full Text] [Related]
16. Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
Chen YB; Mohty M; Zeiser R; Teshima T; Jamy O; Maertens J; Purtill D; Chen J; Cao H; Rossiter G; Jansson J; Fløisand Y
Nat Med; 2024 Jun; ():. PubMed ID: 38844797
[TBL] [Abstract][Full Text] [Related]
17. Diverting Enterostomy Improves Overall Survival of Patients With Severe Steroid-refractory Gastrointestinal Acute Graft-Versus-Host Disease.
Khodr J; Zerbib P; Rogosnitzky M; Magro L; Truant S; Yakoub-Agha I; Duhamel A; Seguy D
Ann Surg; 2021 Nov; 274(5):773-779. PubMed ID: 34342300
[TBL] [Abstract][Full Text] [Related]
18. [Anti-CD(25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic stem cell transplantation].
Tao T; Xue SL; Chen F; Xu Y; Ma X; Miao M; Tang XW; Wu DP
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):324-329. PubMed ID: 29747286
[No Abstract] [Full Text] [Related]
19. Tocilizumab for steroid refractory acute graft-versus-host disease.
Roddy JV; Haverkos BM; McBride A; Leininger KM; Jaglowski S; Penza S; Klisovic R; Blum W; Vasu S; Hofmeister CC; Benson DM; Andritsos LA; Devine SM; Efebera YA
Leuk Lymphoma; 2016; 57(1):81-5. PubMed ID: 26140610
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract.
Ganetsky A; Frey NV; Hexner EO; Loren AW; Gill SI; Luger SM; Mangan JK; Martin ME; Babushok DV; Drobyski WR; Smith J; Timlin C; Freyer CW; Stadtmauer EA; Porter DL
Bone Marrow Transplant; 2019 Feb; 54(2):212-217. PubMed ID: 29795429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
